BIOFRONTERA AG/ADR (NASDAQ:BFRA) was downgraded by research analysts at Lake Street Capital from a “buy” rating to a “hold” rating in a note issued to investors on Friday, The Fly reports. They currently have a $11.00 target price on the stock, down from their prior target price of $17.00. Lake Street Capital’s price objective points to a potential downside of 12.56% from the company’s previous close.

Shares of NASDAQ BFRA traded up $0.72 during trading on Friday, hitting $12.58. 32 shares of the company were exchanged, compared to its average volume of 1,173. The company has a market cap of $264.67 million, a price-to-earnings ratio of 395.33 and a beta of 0.87. BIOFRONTERA AG/ADR has a 1 year low of $11.04 and a 1 year high of $18.32. The firm’s fifty day moving average price is $14.02 and its 200 day moving average price is $15.03. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.48 and a quick ratio of 2.23.

BIOFRONTERA AG/ADR (NASDAQ:BFRA) last issued its earnings results on Tuesday, August 27th. The company reported $0.58 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.82. The company had revenue of $7.98 million for the quarter. BIOFRONTERA AG/ADR had a net margin of 4.48% and a return on equity of 6.82%.

BIOFRONTERA AG/ADR Company Profile

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis.

Featured Article: Profit margin is different from the revenue

The Fly

Receive News & Ratings for BIOFRONTERA AG/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOFRONTERA AG/ADR and related companies with MarketBeat.com's FREE daily email newsletter.